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In vivo quantification of ultrasound targeted
microbubbles to enhance cancer assessment
Claudia Scialleroa*, Emanuele Dagliob and Andrea Truccoa,c
Contrast-enhanced ultrasound with targeted microbubble contrast agents is an emerging technique for imaging bi-
ological processes at the molecular level. The accumulation of targeted microbubbles at tissue sites overexpressing
specific molecular markers increases the backscattered signal for noninvasive evaluations of diseases. The aim of
this preliminary study was to combine molecular imaging with an in vivo contrast agent quantification to support
the early diagnosis of the pathology and to enhance the assessment of neoplastic tissues. Tumor growth was in-
duced by subcutaneous injection of prostate cancer cells in four rats. Microbubbles targeted to tissue factor (TF)
were administered. A vascularized region located in proximity to the tumor and centered around the focus depth
was analyzed in each animal. The backscattered signals (i.e. the radio-frequency data) were acquired during two dif-
ferent perfusion conditions to evaluate the contribution of attached microbubbles. After image generation by means
of a multi-pulse contrast-enhanced technique, a nonlinear regression method based on the support vector machine
was employed to estimate the contrast agent concentrations in cubic voxels (1-mm side length). The number of at-
tached microbubbles per mm3 was estimated based on a multi-dimensional vector of features extracted from the
processed radio-frequency signals. A significant correlation (p<0.05) between the size of the tumors and the esti-
mated microbubble concentration was found, thus opening the possibility for combining molecular imaging and
contrast agent concentration mapping to refine pathology evaluation. Copyright © 2016 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Molecular imaging with ultrasound targeted contrast agents
(CAs) is based on the same general concept used for the
targeting of optical imaging dyes, radiopharmaceuticals and
magnetic resonance imaging (MRI) CAs. Specific ligands able to
adhere to targets on the cell surface under disease-specific con-
ditions are coupled to the CA particle (1). In the case of ultra-
sound molecular imaging, the protective shells of gas-filled
microbubbles (MBs) comprising ultrasound CAs are typically
modified to allow selective binding to cellular epitopes or other
receptors (i.e. active targeting). Due to the typical size (1 – 8μm)
of MBs (2), they are restricted to the vasculature, implying that
only vascular disease markers can be addressed. Molecular sig-
natures that are overexpressed in regions of angiogenesis or
inflammation can be used to localize the CAs due to comple-
mentary receptor ligands (3). The resultant accumulation of
CAs in the target area increases the backscattered signal. As a
consequence, ultrasound imaging with targeted CAs can provide
higher sensitivity and specificity with respect to non-targeted
agents.
In recent years, a variety of targeted MBs have been prepared
and applied to experiments of in vitro cell-specific targeting and
in vivo molecular imaging. By comparing non-targeted and
targeted MBs, targeted MBs have demonstrated an enhanced
acoustic intensity for facilitating a noninvasive evaluation of
early angiogenesis for real-time imaging (4–7). Angiogenesis
plays a critical role in many disease processes, such as tumor
growth and metastasis. An effective quantification of the accu-
mulated MBs at the target sites provides additional information
for more accurate cancer assessments. This parameter is particu-
larly attractive supposing that MB retention is primarily influ-
enced by the ligand density. In the case of non-targeted MBs,
ultrasound images are supplemented by the quantification of
tissue perfusion, that is the quantification of blood flow using
the image intensity of a region of interest (ROI) as a function of
time, to differentiate malignant from benign tumors in the liver
and to enhance the ultrasound sensitivity for diagnosing breast
and prostate tumors (4,8).
In this study, an in vivo quantification analysis, which evaluates
the concentration of attached targeted MBs, is combined with
ultrasound molecular imaging. We hypothesize that the concen-
tration estimation (expressed as MBs per mm3) inside an ROI
selected by observing the ultrasound image of the scene can
support noninvasive tumor detection and evaluation. The
method developed by us (9) for the estimation of the MB con-
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centration is significantly different from a straightforward analy-
sis of the acoustic signal intensity. After a tissue rejection phase,
i.e. a nonlinear imaging technique to abate the contribution
from the surrounding tissue and to emphasize the MB echoes,
a multi-dimensional vector of features is extracted from the re-
sidual backscattered signals. Subsequently, a nonlinear regres-
sion approach based on a support vector machine (SVM) is
applied to estimate the MB concentration in small volumes (i.e.
cubic voxels of 1mm side lengths). To test our assumption, li-
pidic MBs containing targeting molecules were administered to
rats bearing subcutaneous prostate tumors of different sizes.
Targeted ultrasound imaging with a multi-pulse technique was
performed with two different perfusion conditions to evaluate
the contribution of targeted MBs. Radio-frequency (RF) signals
were collected to quantify the MB concentration by off-line data
processing. The obtained results were then correlated with the
tumor extensions. To the best of our knowledge, this is the first
study addressing the combination of molecular imaging and
in vivo quantification analyses of targeted MBs.
2. MATERIALS AND METHODS
2.1. Targeted CA
In addition to the different vascular epithelial growth factor
receptors (VEGFR), tissue factor (TF) is a potential vascular marker
linked to tumor angiogenesis (10). TF has been reported to be
expressed in tumor vessels in prostate cancer but not in the
endothelium in healthy tissues (11). Soft-shell MBs (average di-
ameter of 1.8μm) with attached anti-TF antibodies were used
as contrast media. The ligand density was on the order of
2 × 104 per MB. The average number of bound antibodies per
square micrometer was approximately 2300. In vitro and in vivo
tests demonstrated the binding efficiency of these targeted
MBs, and a significant signal enhancement was found with re-
spect to non-targeted MBs (12,13). Further details on the
targeted CA used in this study can be found in (12,13).
2.2. Molecular imaging and CA quantification
Molecular imaging and CA quantification can be combined by
processing the acquired RF data. A general approach was pro-
posed by the authors in (9) and can be divided into three steps:
1) tissue rejections by means of a contrast-enhanced signal pro-
cessing technique; 2) image generation and ROI localization; and
3) an estimation of the CA concentration.
In the first step, a non-destructive, multi-pulse imaging tech-
nique that avoids MB destruction by using moderate acoustic pres-
sures was applied for CA detection. This technique is one of the
contrast pulse sequences (CPS) based on the transmission of three
pulses (14) and exploits the nonlinear backscattered signal gener-
ated by MBs. A given pulse scaled in amplitude by the coefficients
0.5, –1, and 0.5 was transmitted three times, and the corresponding
echoes were added with unitary coefficients. In this way, both the
second- and third-order nonlinear terms are preserved, whereas
the linear term, where tissues are predominant, is abated. A band-
pass filter centered on the fundamental frequency can be conve-
niently applied to maintain only the third nonlinear component
on the fundamental bandwidth, as discussed in (15). The processed
RF signals are used to both generate the ultrasound image and to
supply the input data for the concentration estimation procedure.
In detail, a MATLAB (The MathWorks, Inc., MA, USA) script reads
the RF frames that were acquired by the ultrasound scanner and or-
ganizes them into a three-dimensional (3D) matrix. The three
dimensions of the matrix represent the number of lines of sight
generated by the beamformer for the ultrasound image genera-
tion, the number of RF time samples for each line of sight, and
the number of transmitted pulses (three for the CPS technique
we adopted). The 3D matrix is reduced to a two-dimensional (2D)
matrix by summing the three pulses that were acquired for each
line of sight, according to the CPS strategy. Subsequently, as de-
scribed above, band-pass filtering is applied through a FIR-filter that
operates along the temporal dimension of the matrix. At this stage,
the 2D RF data matrix can be used for ultrasound image rendering.
During the second step, the same functions as those typically
used by the back-end of medical ultrasound scanners (i.e. enve-
lope detection and logarithmic compression) were applied. After
the image generation, an ROI was identified. The ROI identified a
thin tissue slice whose surface is defined on the imaging plane
and whose thickness (in the elevation plane, perpendicular to
the imaging plane) can be considered constant. Thus, the ROI
can be considered as a single layer of voxels whose minimum
size depends on the resolution of the ultrasound imaging sys-
tems along the three orthogonal axes. Notably, because the 2D
RF data matrix obtained at the end of the previous step corre-
sponds to the imaging plane, each voxel contains Ξ lines of sight
and Ω time samples, depending on the voxel size.
In the last step, the concentration estimation was performed.
First, the Ξ RF signals and the Ω time samples contained inside
each voxel of the ROI were identified on the 2D RF data matrix,
depending on the specific position of the voxel. Then, for every
RF signal segment contained inside a given voxel, the following
features were computed: the signal energy, expressed on a log-
arithmic scale; the kurtosis of the normalized signal; the number
of peaks of the normalized signal that exceed 20% of the signal
maximum; the number of peaks of the signal envelope that ex-
ceed 90% of the envelope maximum; and the number of peaks
of the signal spectrum whose magnitude is between the spec-
trum maximum minus 20 dB and the maximum itself. Thus, for
each feature, Ξ values were collected, i.e., one value for each line
of sight contained inside the voxel. The final value of each fea-
ture of a given voxel was computed by averaging the Ξ values.
To cope with a potential nonlinear dependency of the concen-
tration from the extracted features, a nonlinear regression
method based on the SVM was developed and experimentally
validated (9) through in vitro tests, as briefly described in the
next subsection. The training phase of the statistical regressor re-
quires a large pool of signals generated from voxels that contain
a given and well-known number of MBs. In addition, a large pool
of signals is necessary for each possible concentration. The com-
bination of these two requirements makes it extremely difficult
(if not impossible) to collect all the signals necessary to build a
satisfactory training set from real experiments. As a conse-
quence, a numerical model that encompassed the transmission,
propagation, tissue and MB scattering, reception and processing
of the ultrasound signal was used to simulate the RF signal
achieved for a given MB concentration (9,15). The simulation
model was generated according to the operating conditions
used for the real experiments (e.g. probe characteristics, trans-
mitted signal waveforms, imaging technique, focus depth, voxel
size, and noise spectrum) and was calibrated through the analy-
sis of some real signals (9), as described in the next subsection.
Thus, a completely synthetic training phase was possible. The re-
gression model for the relationship between the features and
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MB concentration obtained from the training phase was then
applied to estimate the concentration, taking as input the fea-
tures extracted from real signals.
2.3. In vitro calibration and validation
In vitro experiments were performed under controlled conditions
(9) to calibrate the simulation model and test the accuracy of the
concentration estimator based on a synthetic training phase.
As reported in (9), an inverted brightfield/phase contrast
microscope equipped with a fast greyscale camera was used to
count the number of bubbles (i.e. the real concentration)
attached to a wall of a small flow channel immersed in a material
that mimics tissue and is optically and acoustically transparent.
The microscopy images represent 1mm3 of the upper wall of
the channel. Different simultaneous optical-acoustic acquisitions
were performed to compare real and estimated concentrations
according to the setup conditions reported in (9). During these
tests, seven concentrations were observed using the optical
equipment: 11, 19, 36, 54, 75, 86, and 98 MBs/mm3. For each con-
centration, the ultrasound backscattered signals were acquired
several consecutive times.
Such signals were used to derive the average contrast to tissue
ratio (CTR, i.e. the ratio between the received energy of the MB
response and that of the tissue response) as a function of MB
concentration. The observed CTR curve was used to weight the
tissue and MB responses generated by the simulation model be-
fore their final addition in such a way that simulated and
backscattered signals showed similar CTR values. In this way, a
calibrated simulation model was attained.
Then, our concentration estimation method based on a syn-
thetic training phase (performed using signals that were gener-
ated by the calibrated simulation model) was validated by
comparing the estimated and real concentration values. The re-
sults of this test are described in (9); in general, the absolute
value of the average error did not exceed 4 MBs/mm3. An error
of 5 MBs/mm3 was reported for only one concentration. Al-
though these results represented positive experimental valida-
tion of the proposed method, this previous study failed to
evaluate the achievable performance when the training phase
is performed using real signals (9). We used the same signals
and methods as in (9) to perform this evaluation; we compared
the estimations obtained when the training set was composed
of synthetic signals with those obtained when the training set
was composed of real signals. The test set was the same for
the two training options and was composed of real signals. Re-
gardless, the signals for the test set were different from those
used for the training phase. The comparison of the results ob-
tained with the two training options demonstrated that for all
the MB concentrations considered in this paper, the differences
between the average estimated values did not exceed 4
MBs/mm3. Therefore, we verified that the concentration estima-
tions obtained by training the statistical regressor with synthetic
signals (generated using the calibrated simulation model) were
close to the real values, and furthermore, they were close to
the values estimated using real signals for the training phase.
2.4. In vivo experiments
Targeted MBs were injected intravenously via the tail vein of
adult rats bearing subcutaneous VCaP prostate cancers. For
each injection, 400μL of CA (108 MBs/ml) was administered
and flushed with 600μL of sterile saline. Approximately 4 × 107
MBs were injected into a blood volume of approximately
50mL to obtain a concentration of 8 × 105 MBs/mL (equivalent
to 8 × 107 MBs/kg), which is on the order of the concentration
used for a human bolus injection (16). A modified version of a
MyLab70XVG ultrasound scanner (Esaote S.p.A., Genoa, Italy)
developed for research purposes and equipped with a special
frame grabber board that collects the RF signals at the
beamformer output was used. The ultrasound scanner was con-
nected to a linear array probe with a central frequency of 5MHz
and a fractional bandwidth of 90%. To avoid any movement
concerns and related artefacts, the ultrasound probe was me-
chanically fixed using an articulated arm, and the animals were
anesthetized. The pulses transmitted according to the CPS tech-
nique were 5-cycle, Gaussian-shaped signals with a central fre-
quency of 5.2MHz. For reception, the grabber board collected
the three backscattered signals for each line of sight. For all
experiments, the negative peak pressure at the focus depth
(placed 1.7 cm below the probe) was 100 kPa, corresponding
to a mechanical index (MI) of 0.04. Due to the specific character-
istics of the adopted probe and pulses, the axial, lateral and el-
evation resolutions enabled the definition of cubic voxels with
1mm sides. The numbers of lines of sight and time samples of
the 2D RF data matrix contained inside each voxel were Ξ = 6
and Ω = 80, respectively. In Fig. 1, the mean acoustic intensity
in the ROI (i.e. a well-perfused area inside the tumor and sur-
rounding neovessels) was monitored for 6min. RF signals were
acquired every 30 s and were processed using a script. A signif-
icant contrast-enhancement due to flowing and adherent MBs
was recorded following CA injection. A plateau was reached
after 3.5min. To evaluate the concentration of adherent MBs,
the image was analyzed under two perfusion conditions. A first
RF signal acquisition was performed between 3.5 and 4min
after the CA injection. The acquired signals contained the contri-
bution of flowing and adherent MBs. Immediately after, the MBs
were destroyed by a high-intensity pulse (an acoustic pressure
higher than 1MPa, corresponding to an MI of 0.5). Thirty
seconds after the destruction, RF signals were acquired for a
second time. In this case, the signals mainly contained contribu-
tions from the flowing MBs because in a 30 s interval, the MBs
could not adhere to target sites (12). A similar protocol was used
for the ultrasound image analysis of targeted MBs in (5). The
concentration of attached MBs was estimated starting from
the two data acquisition periods: the final estimate was derived
Figure 1. Average acoustic intensity in the ROI (well-perfused areas in
the tumor and surrounding vessels) for 6min after the injection of
targeted MBs and the intensity curve trend using a 6th order polyno-
mial fit.
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by subtracting the concentration estimated after the MB de-
struction from the concentration estimated before the MB
destruction.
3. RESULTS AND DISCUSSION
Initially, the subcutaneous tumors were imaged in B-mode (i.e.
on-line image acquisition in standard mode) without the admin-
istration of CA. Because all tumors were confined to a specific
area (i.e. the encapsulated tumors), the sizes were recorded by
means of the electronic calipers on the ultrasound system. An
example is shown in Fig. 2. The four animals were analyzed,
and the areas of their tumors on the ultrasound images were
27, 33, 54, and 94mm2. In the first two cases, the sizes were
similar.
After the CA administration, the previously described protocol
was applied. In Fig. 3, the contrast-enhanced ultrasound images
obtained from the off-line processing of the signals acquired be-
fore and after the MB destruction are shown. As seen in Fig. 3(a),
acquired 4min after administration, the flowing and adherent
MBs were present. As seen in Fig. 3(b), acquired 4.5min after ad-
ministration (which corresponded to 30 s after the MB destruc-
tion), flowing MBs were primarily present. To emphasize the
contribution of the adherent MBs, the difference image was
computed. This result is shown in Fig. 3(c) in a logarithmic scale
(as for the previous images) and a false-color palette. A few spu-
rious artefact contributions and speckle noise are present but are
easily distinguishable.
The visual analysis of these images enabled the delineation of
a rectangular ROI for each examined tumor. The ROIs were
regions inside which the estimations of the MB concentrations
were performed. The ROIs were placed around the focus depth
(1.7 cm below the probe, close to the lower interface between
the tumor and tissues) and included well-perfused areas inside
the tumor and surrounding neovascular tissues. In Fig. 4, the
contrast-enhanced ultrasound images of the four tumors ac-
quired before and after the MB disruption and the related con-
centration maps are shown. The position of the ROI for each
tumor is specified by the superposition of a red grid on the cor-
responding ultrasound images. A concentration map shows the
estimated concentration of adherent MBs for each cubic voxel
in the related ROI. The voxels composing an ROI are represented
in Fig. 4 as a grid of small squares whose grey levels express the
estimated concentrations.
To support the analysis of the results and to compare the four
experiments, Fig. 5 displays two histograms that show the fol-
lowing for each tumor: (a) the sample mean and standard devi-
ation of the estimated MB concentration inside the related ROI;
and (b) the relative frequency of the voxels with estimated MB
concentrations of less than 10 MBs/mm3, greater than 20
MBs/mm3, and greater than 30 MBs/mm3. The correlation
between the tumor size and the estimated MB concentration
was determined using a correlation coefficient r, keeping the p-
value less than 0.05. We verified the existence of a significant
correlation between the tumor size and the sample mean of
the estimated attached MBs concentration in the ROI (r=0.877,
p< 0.05). Moreover, the analysis of the second graph reveals that
concentrations less than 10 MBs/mm3 are predominant when
small tumors are considered (r=0.793, p< 0.05), whereas the
percentage of voxels with a concentration greater than 20
MBs/mm3 increases with tumor size (r=0.893, p< 0.05). Finally,
for the tumors with sizes of 27mm2 and 33mm2, the estimated
concentrations for the ROI voxels did not exceed 30 MBs/mm3,
whereas for the 94mm2 tumor, the percentage of voxels with
concentrations greater than 30 MBs/mm3 was approximately
50%. The correlation observed between the relative frequency
of voxels that exceeded 30 MBs/mm3 and the tumor size was
particularly high (r= 0.944, p< 0.05).
The correlation between the tumor size and the estimated CA
concentration can be explained as follows. The growth of most
solid tumors is highly dependent on local vascular proliferation
(4). A higher vascularization with an increased cancer cell
density and molecular markers occurs when the size of the
tumor increases. Consequently, the increased number of target
sites facilitates the accumulation of targeted MBs. The proposed
Figure 2. B-mode ultrasound image of the subcutaneous tumor
acquired during the size evaluation phase. CA was not administered.
Figure 3. Contrast-enhanced ultrasound images acquired: (a) 4min after CA injection; (b) 30 s after MB destruction (i.e., approximately 4.5min after CA
injection). The difference image (c) shows the attached MB contribution. The image brightness is expressed on a logarithmic scale.
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quantification method, based on a nonlinear regression tech-
nique, is a powerful tool that is more sensitive and accurate
than conventional image intensity analysis methods (9).
Considering that the subtraction procedure used in this study is
prone to motion artefacts, it is interesting to note that the free-
flowing MB contribution can be rejected by strategies that do
Figure 4. Ultrasound images before (left column) and after MB disruption (center column) and the related concentration maps (right column) for the
adherent targeted MBs. The tumor sizes for the four analyzed mice were: (a) 27mm2; (b) 33mm2; (c) 54mm2; and (d) 94mm2. The image brightness is
on a logarithmic scale; the CA concentration is on a linear scale, measured in MBs/mm3.
Figure 5. (a) Sample mean and standard deviation of the MB concentration estimated for each tumor. (b) Relative frequency of the voxels with an
estimated MB concentration less than 10 MBs/mm3, greater than 20 MBs/mm3 and greater than 30 MBs/mm3. The four experiments are indexed from
1 to 4 according to the tumor size, in ascending order.
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not require a MB destruction step and that are more compliant
with clinical practice (even if they can be less accurate in rejecting
the flowing MB contribution). For instance, in (7), the free-flowing
MBs are distinguished from attached MBs by waiting for a suffi-
ciently long time interval (e.g. seven minutes from the MB injec-
tion) to allow both MB accumulation at target sites and unbound
MB clearance. This alternative protocol can be easily adopted in
combination with the concentration estimation method that we
proposed to correlate MB accumulation with tumor size.
4. CONCLUSIONS
In vivo experiments were performed to explore the possibility of
combining molecular imaging with targeted CA quantification to
obtain additional information useful for cancer assessment. The
results demonstrated a significant correlation between the size
of the tumor and the estimated concentrations of the adherent
MBs. Thus, CA quantification has the potential to support the
early diagnosis of cancer pathology by localizing and evaluating
tiny quantities of neoplastic tissues that are difficult to assess by
conventional ultrasound image intensity analyses. Moreover, the
combination of molecular imaging and CA quantification repre-
sents additional degrees of assessment after basic diagnostic
procedures (e.g. PSA and DRE screening in the case of prostate
cancer). The improvement of the cancer detection rate during bi-
opsy exams is another potential medical application. An echo-
guided biopsy supported by the quantification of the targeted
CAs in the ROI could help prevent a high number of false nega-
tives and enhance the exam sensitivity.
Acknowledgements
The authors are grateful to Prof. F. Frauscher, Dr. J. Gradl and Dr.
M. Abdellah for animal preparation and their assistance with the
experiments. Additionally, the assistance of Dr. P. Pellegretti and
Dr. M. Crocco with the data acquisition is gratefully acknowl-
edged. The authors also thank Esaote S.p.A., Genova, Italy, for
the equipment support.
REFERENCES
1. Klibanov AL. Ultrasound molecular imaging with targeted
microbubble contrast agents. J Nucl Cardiol 2007; 14: 876–884.
2. Cosgrove D. Ultrasound contrast agents: an overview. Eur Radiol
2006; 60: 324–330.
3. Hauff P, Reinhardt M, Foster S. Ultrasound contrast agents for molec-
ular imaging. In Handbook of Experimental Pharmacology. Molecular
Imaging I, Semmer W, Schwaiger M (eds). Springer-Verlag: Berlin,
2008; 223–245.
4. Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S, Shaffrey
ME, Sklenar J, Lindner JR. Imaging tumor angiogenesis with contrast
ultrasound and microbulles targeted to αvβ3. Circulation 2003; 108:
336–341.
5. Stieger SM, Dayton PA, Borden MA, Caskey CF, Griffey SM, Wisner ER,
Ferrara KW. Imaging of angiogenesis using CadenceTM contrast pulse
sequencing and targeted contrast agents. Contrast Media Mol Imag-
ing 2008; 3: 9–18.
6. Deshpande N, Needles A, Willmann JK. Molecular ultrasound imag-
ing: current status and future directions. Clin Radiol 2010; 65:
567–581.
7. Anderson CR, Hu X, Tlaxca J, Decleves A-E, Houghtaling R, Sharma K,
Lawrence M, Ferrara K, Rychak JJ. Ultrasound molecular imaging of
tumor angiogenesis with an integrin targeted microbubble contrast
agent. Invest Radiol 2011; 46(4): 215–224.
8. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-
enhanced US for detection. Radiology 2001; 219: 219–225.
9. Sciallero C, Crocco M, Trucco A. A method for estimating the
microbubble concentration in contrast-enhanced ultrasound imag-
ing. Meas Sci Technol 2011; 22: 114009 (9pp).
10. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteo-
pontin, αvβ3 integrin expression inmicrovasculature of gliomas asso-
ciated with vascular endothelial growth factor expression. Br J
Cancer 2000; 82(12): 1967–1973.
11. Hu Z, Garen A. Targeting tissue factor on tumor vascular endo-
thelial cells and tumor cells for immunotheraphy in mouse models
of prostatic cancer. Proc Natl Acad Sci U S A 2001; 98(21):
12180–12185.
12. Zerbe I, Gajovic-Eichelmann N. Lipidic microbubble targeting of
surface proteins using an in vitro system. In Ultrasound contrast
agents. Targeting and processing methods for theranostics,
Paradossi G, Pellegretti P, Trucco A (eds). Springer-Verlag: Milan,
2010; 41–52.
13. Hauwel M, Bettinger T, Allemann E. Use of microbubbles as ultra-
sound contrast agents for molecular imaging. In Ultrasound contrast
agents. Targeting and processing methods for theranostics,
Paradossi G, Pellegretti P, Trucco A (eds). Springer-Verlag: Milan,
2010; 13–23.
14. Phillips PJ. Contrast pulse sequences (CPS): imaging nonlinear
microbubbles. Proc. 2001 IEEE Ultrasonics Symposium, Atlanta, GA,
2001; 2: 1739–1745.
15. Crocco M, Palmese M, Sciallero C, Trucco A. A comparative analysis of
multi-pulse techniques in contrast-enhanced ultrasound medical im-
aging. Ultrasonics 2009; 49: 120–125.
16. Schneider M. Characteristics of SonoVueTM. Echocardiography 1999;
9(7): 743–746.
C. SCIALLERO ET AL.
wileyonlinelibrary.com/journal/cmmi Copyright © 2016 John Wiley & Sons, Ltd. Contrast Media Mol. Imaging 2016, 11 313–318
318
